All posts by medical

From ‘Grey’s Anatomy’ to ‘Homeland’: 12 TV shows that went on for too long – The National

When it was announced that The Walking Dead would be ending after 11 seasons, some fans couldnt help but wonder: what took so long?

The post-apocalyptic horror show, which made its debut in 2010, was initially met with positive feedback from fans and critics, but as the series went on, reviews became mixed and some were left to question whether it was still worth their time.

However, The Walking Dead isn't the only show to suffer such a fate. There have been many shows that started off strong, but have faded over time due to a decline in quality. We take a look at 12 other shows (including two that are still running) that perhaps should have quit while they were ahead...

Warning: spoilers ahead

The show about a serial killer who targeted serial killers started strongly enough, but seemed to lose its way towards the end. After following Dexter Morgan and his killing compulsion for eight seasons, fans were curious to know how his story would end. Rather than being caught for his murders (spoiler: he wasnt) or having a happy ending with his girlfriend (spoiler: he didnt), he instead buries his sister (spoiler: who he didn't kill) at sea and lives out the rest of his life as a lonely lumberjack. Thats it.

Fans were undoubtedly frustrated with this letdown of an ending after committing for eight long years, which was all about a building tension of what would happen to ol' Dex.

There's no doubt US sitcom Friends is beloved by many around the world, but some have wondered whether the show, which follows six friends living in Manhattan, went on for just a little too long.

Lasting 10 seasons, none of the main characters seemed to evolve much over the years and towards the end, they had become mostly caricatures of themselves. Plus, the later seasons featured some questionable storylines (cough, Joey and Rachel, cough) which left fans scratching their heads.

This sitcom about three diverse but connected families had a long run, lasting for 11 seasons. Shot in a mockumentary style setting, the first few seasons of the show were so well received that the series was nominated for the Emmy Award for Outstanding Comedy Series in each of its first eight seasons, winning five years straight (from 2009 to 2014). However, as it rumbled on, the show seemed to lose some of its magic, along with its Emmy recognition and sky-high ratings, before coming to an end in April 2020.

The Netflix original starring Kevin Spacey and Robin Wright as an aspiring presidential powerhouse couple (and then later as a presidential couple) was a hit for the streaming platform when it debuted. While it was only six seasons long, the absence of Spacey (who was dropped from the series following sexual misconduct allegations) was noticeable in the final season. Even though Wrights performance was heavily praised, season six just couldnt come together for fans, with many feeling like it went on at least one season too long.

The Netflix series, based on the 2007 best-selling young adult novel by Jay Asher, follows the story of a high-school teen named Hannah Baker who falls deeper into despair after being bullied, culminating in her death. She leaves behind tapes that detail 13 reasons why she was driven to end her own life in an audio diary. The first season, which followed the novel, was so well received that Netflix ordered more seasons. However, seasons two through four featured storylines that moved away from the show's main premise, Hannahs death, leaving some fans to question whether the show was just trying to string things out.

The Big Bang Theory, which ran for 12 seasons, is a divisive show: people either love it or hate it with no in-between. The comedy series follows the everyday lives of four nerdy friends and their free-spirited, wannabe actress neighbour. Set in Pasadena, California, the show is riddled with pop culture references and jokes, and even had its own catchphrase of bazinga thanks to the character Sheldon Cooper. However, as brilliant as the show may have been at times, 12 years worth of bazingas was a little much.

The US spy thriller starring Claire Danes as Carrie Mathison, a CIA officer with bipolar disorder, wrapped up its eighth and final season in 2020. When the show debuted in 2011, it received near universal praise, winning the Emmy for Outstanding Drama Series and the lead actors winning Emmys as well. However, as it went on and on, many fans felt it lost its impact, making it one of the few shows that seems to be remembered fondly for only one season alone.

The Office US ran for nine seasons and was an adaptation of the much-loved British series of the same name, starring Ricky Gervais. It followed the everyday lives of office employees at the fictional Dunder Mifflin Paper Company. While the show was raved about in its early seasons, it was season seven that stood out to most fans, as it was Steve Carell's last as regional manager Michael Scott. For many fans, it was all downhill from there.

Who doesnt enjoy a good love story? Unfortunately, after nine seasons, fans didnt get quite the ending they had been hoping for. The show focuses on Ted Mosby and his friends who live in New York City, narrated by "future Ted" telling his children the story of how he met their mother. But of course, its not that simple, and he takes a long time to get to the point. While the first few seasons were met with rave reviews, later reviews were mixed. The ninth season is particularly decisive as all 24-episodes take place over a single weekend (did the writers run out of ideas?), while the finale episode jumped into the future with a seemingly rushed ending that undid nine years worth of build-up.

The longest running sci-fi genre series on American TV, Supernatural has been on the air for 15 years. The show stars Jared Padalecki and Jesen Ackles as brothers who hunt supernatural beings such as demons, ghosts and monsters. While there are some interesting storylines and subplots, theres only so much writers can change up every season before fans start wondering whether the series has passed its expiration date. Luckily, its 15th season, airing this year, is its last.

The long-running animated series follows the Simpson family and is the longest US sitcom in history, having first aired in 1989. The first 10 seasons of the show received praise for having humour, wit, and intelligence, with many calling it the golden era for the show. While the series still receives Emmy recognition, nominated yearly for Outstanding Animated Programme, some critics (as well as fans) believe the show has been on a decline in recent years, with some questioning when it will finally just call it quits.

The US medical drama series focuses on the personal and professional lives of surgical interns and their mentors. It follows the titular character Dr Meredith Grey, which fans have seen go from intern to chief of general surgery over the course of the show. While the series has been praised for its emotional storytelling and its fair share of pop culture moments (who could ever forget Meredith asking Derek Shepherd to pick me, choose me, love me?), some do wonder if the show has gone on for just a bit too long.

After all, Meredith has already endured her fair share of tragedy including the death of her sister, mother, husband, and numerous friends, as well as surviving a hospital shooting and a plane crash. How much more can one person go through?

Updated: September 22, 2020 11:57 AM

Read more:
From 'Grey's Anatomy' to 'Homeland': 12 TV shows that went on for too long - The National

‘Grey’s Anatomy’: Sarah Drew’s Recent Instagram Post About Jackson and April Has Fans Itching for a Reunion – Showbiz Cheat Sheet

The countdown to Greys Anatomy Season 17 has officially begun. Recently, the cast and crew started production on the new season, which will be released on ABC starting Thursday, Nov. 12. Of course, this means the fandom is buzzing. But no one is quite as excited as Sarah Drew (April Kepner), who supported the shows return with a sweet Greys Anatomy throwback alongside Jesse Williams (Jackson Avery). So naturally, viewers are begging for a Japril reunion.

RELATED: Greys Anatomy: 3 Love Confessions Fans Will Never Forget

For anyone who needs a refresher, Jackson and April didnt end up together on Greys Anatomy. The couples rollercoaster romance ended in divorce. However, they had a daughter, Harriet Kepner-Avery, and decided to co-parent.

Meanwhile, Drew left after the Greys Anatomy Season 14 finale. On the show, April quit her job at Grey Sloan Memorial to provide medical care for homeless communities. That said, the character is still in Seattle.

April also received her happy ending with Matthew Taylor (Justin Bruening), the man she left at the altar in season 10. Then in her final episode, April and Matthew got married as Jackson supported them both as a friend.

RELATED: Greys Anatomy: Are Jesse Williams and Sarah Drew Friends in Real Life?

In early September 2020, the Greys Anatomy Season 17 cast returned to set to start filming. Then in an Instagram post published on Sept. 14, Drew honored the cast and crew with a throwback to Jackson and April from the season 12 episode titled Unbreak My Heart.

In honor of my pals over at Greys starting back up this past week, heres a fun throw back to #japrilthemovie, Drew wrote. Our amazing director for that episode, #robcorn sent this photo to us over the weekend. This episode will go down as one of my all time favorite television experiences. Every one of those 9 days on set was joyous.

The actor highlighted writer Elizabeth Klaviter and director Rob Corn for their involvement with the episode. Then she reflected on her experience.

We felt like we were in this magical little bubble making our own movie, Drew wrote. This pic is from the rehearsal of that epic 15-page scene that ended with us pelting each other with fortune cookies. We spent a whole day (12-13 hours) shooting that one scene together. It felt like we were performing a one act play and it was really hard work but a profoundly fulfilling experience.

She added, Sending love to all the #japril fans out there and of course, to my co-captain @ijessewilliams.

RELATED: Greys Anatomy: Were Jackson and April Meant to Be Together? Justin Bruening Doesnt Think So

Drews heartfelt Instagram post had Greys Anatomy fans hoping for a reunion between Jackson and April. Many viewers also noted they missed the actors presence on the ABC medical drama. So would Drew ever return? When speaking with Entertainment Tonight in 2019, the Shondaland star hinted she would never say never.

I will never close the door on my family at Greys, Drew said. It just depends. Its a hard question to answer because it is not an opportunity that has presented itself.

At this point, no one knows whether well ever see a Japril reunion on Greys Anatomy. But whatever happens in the future, its clear Drews experience on the Shondaland drama was something extraordinary.

Check out Showbiz Cheat Sheet on Facebook!

Link:
'Grey's Anatomy': Sarah Drew's Recent Instagram Post About Jackson and April Has Fans Itching for a Reunion - Showbiz Cheat Sheet

Rising Demand for Biochemical Diagnostic Reagent Market Research Report by Manufacturers, Region, Type and Application, Forecast to 2026 – The Daily…

Up-To-Date research on Biochemical Diagnostic Reagent Market 2020-2026 :

From the ocean of Garner Insights database regards to recent market research scenario; Global Biochemical Diagnostic Reagent market exhibits the comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2026. On the basis of historical data, Biochemical Diagnostic Reagent market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Biochemical Diagnostic Reagent industry is likely to appear as a commendable platform for emerging Biochemical Diagnostic Reagent market investors.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak..

Get a Sample PDF copy of the report https://garnerinsights.com/Global-Biochemical-Diagnostic-Reagent-Market-Insights-Forecast-to-2026#request-sample

Topmost Leading Manufacturer Covered in this report:, Roche, Siemens Healthineers, Beckman Coulter, Randox, BioSino, Beijing Leadman Biochemistry, FosunPharma, Beijing Strong Biotechnologies, Dojindo Laboratories, Sysmex, KAINOS Laboratories,.

Product Segment Analysis:, Liquid Double Reagent, Dry Powder Double Reagent,,.

Application Segment Analysis, Hospital, Clinic, Laboratory,,.

Geographically it is divided Biochemical Diagnostic Reagentmarket into seven prime regions which are on the basis of sales, revenue, and market share and growth rate.United States, EU, Japan, China, India, Southeast Asia.

Ask For Instant Discount @ https://garnerinsights.com/Global-Biochemical-Diagnostic-Reagent-Market-Insights-Forecast-to-2026#discount

Key features of this report are:It provides valuable insights into the Global Biochemical Diagnostic Reagent Market.Provides information for the years 2020-2026. Important factors related to the market are mentioned.Technological advancements, government regulations, and recent developments are highlighted.Advertising and marketing strategies, market trends, and analysis are studied in this report.Growth analysis and predictions until the year 2026.Statistical analysis of the key players in the market is highlighted.Extensively researched market overview.

The content of the study subjects, includes a total of 15 chapters:Chapter 1: To describe Biochemical Diagnostic Reagent product scope, market overview, market opportunities, market driving force and market risks.Chapter 2: To profile the top manufacturers of Biochemical Diagnostic Reagent, with price, sales, revenue and global market share in 2018 and 2020.Chapter 3: The Biochemical Diagnostic Reagent competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4: The Biochemical Diagnostic Reagent breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9: To break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11: To segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Biochemical Diagnostic Reagent market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026.Chapter 13, 14 and 15: To describe Biochemical Diagnostic Reagent sales channel, distributors, customers, research findings and conclusion, appendix and data source.

View Full Report @ https://garnerinsights.com/Global-Biochemical-Diagnostic-Reagent-Market-Insights-Forecast-to-2026

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: [emailprotected]

Read this article:
Rising Demand for Biochemical Diagnostic Reagent Market Research Report by Manufacturers, Region, Type and Application, Forecast to 2026 - The Daily...

Itaconic Acid Market Incredible Possibilities, Growth Analysis and Forecast To 2025 |Alpha Chemika, Chengdu Jinkai Biology Engineering, Itaconix…

Overview Of Itaconic Acid Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Itaconic Acid Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Itaconic Acid Market competition by top manufacturers as follow: , Alpha Chemika, Chengdu Jinkai Biology Engineering, Itaconix Corporation, Jinan Huaming Biochemistry, Shandong Zhongshun Science & Technology Development, Spectrum Chemical, Zhejiang Guoguang Biochemistry, Nanjing Huajin Biologicals, Qingdao Langyatai Group, Qingdao Kehai Biochemistry, Ronas Chemicals, Shandong Kaison Biochemical,

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/141740

The global Itaconic Acid market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: SynthesisFermentation

Market Segment by Applications, covers:PlasticizerLubricating Oil AdditiveOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/141740

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Itaconic-Acid-Market-141740

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read more from the original source:
Itaconic Acid Market Incredible Possibilities, Growth Analysis and Forecast To 2025 |Alpha Chemika, Chengdu Jinkai Biology Engineering, Itaconix...

CSU-SACNAS working to create inclusive community in STEM – College of Natural Sciences – Source

Taking a leadership role

Ricardo Vazquez, a fifth-year CSU student double majoring in biochemistry and molecular biology and biomedical science, is this years SACNAS president. He has been involved with the club since 2018 and joined immediately after transferring from Aims Community College in Greeley.

What drew him to the club, initially, was diversity.

Not everybody in SACNAS identifies as Chicano or is Hispanic or Native American, said Vazquez who identifies as Chicano and is a first-generation student. I really like the community because its not a student organization dedicated to promoting just one under-represented minority, it is an enginWoverarching student organization dedicated to promoting diversity in STEM by allowing underrepresented students the opportunity to have an impact in both their scientific and cultural communities.

Vazquez added: I never thought Id be the president of a student organization I never even thought Id be centered in anything. I really didnt have a community back at my old school. I came to CSU looking to be part of a community, and SACNAS really allowed me to do that. Now, the club is allowing me to take a leadership role, trying to grow it and get everybody take part in the community.

SACNAS has a robust group of advisors, faculty board members, and long-term members who are passionate about science and fostering the success of all people in STEM.

Vazquez added that being part of a community of support has been a tremendous asset, adding that SACNAS is a hub for rewarding mentorship opportunities.

Building a community that empowers us and allows us to ask for help and ask questions and be mentors for each other is really important, because you dont know what you dont know, and there are people in our community that do know and want to help, Vazquez said.

Vazquez found SACNAS through Paul Laybourn, a professor in the Department of Biochemistry and Molecular Biology and advisor for the club.

Diversity and inclusion are the biggest issues in science today, Laybourn said. They are a bigger problem than funding. Diversity and inclusion affect science. Its a national security issue. If you dont have all ideas and minds at the table how can you be prepared to solve problems, to answer questions?

While SACNAS was initially meant to bring representation to a few minority groups, it has evolved to become inclusive of all minoritized groups in STEM.

We want everyone to succeed, Vazquez said. SACNAS main goal is getting students more involved in research so that they can understand fundamentally what its like to be a researcher, Laybourn said. We also seek to create a scientific community that doesnt ask you to adopt a new culture but rather introduce your culture to your research.

SACNAS is also diverse in the disciplines of science it represents. It allows students to speak to each other about their research, which teaches them to communicate about their work outside of their direct field, which is a huge skill, said Shane Kanatous, the SACNAS faculty advisor and Department of Biology professor.

While CSU has many different administrative and student efforts focused on diversity and inclusion, SACNAS is somewhat unique. Everyone in science is big on research, but not everyone is big on diversity and inclusion, said CSU student Vincent Elias, a neuroscience major and the public and marketing relations officer for SACNAS.

This semester, all SACNAS events and meetings will be completely virtual. The club leaders have developed We Hear You, Lets Talk About It, a virtual meeting series in response to the COVID-19 pandemic that provides a safe space for community members designed to foster discourse and support.

According to the organizers, the first few iterations of the meeting have been very successful, and the club leadership is looking forward to growing the community, even in a virtual format.

The club has also taken the time to develop a statement of commitment: To promote diversity within STEM with careful consideration of the Black Lives Matter movement and incidents of racial bias both on and off CSUs campus.

The action we take on campus will prepare us to take action off campus, said Vazquez.

This years SACNAS student leaders give proof that the organization is deeply committed to its mission, and ready to make change at CSU, in STEM, and around the world.

About Rams Shape Science:Meet some of the extraordinary students, faculty, and staff in the College of Natural Sciences who are shaping the future of science and our society.

More:
CSU-SACNAS working to create inclusive community in STEM - College of Natural Sciences - Source

Enhancing overall facial skin wellness: Augustinus Bader reveals The Face Oil – The Moodie Davitt Report – The Moodie Davitt Report

Augustinus Bader is a Silver Partner of The Moodie Davitt Virtual Travel Retail Expo where it is exhibiting in #Virtual Stand BT-S9

Augustinus Bader a Silver Partner at the upcoming Moodie Davitt Virtual Travel Retail Expo has extended its luxury skincare range with The Face Oil.

The new Face Oil offers an ultra-lightweight, fast-absorbing and nourishing formula made with an exact calibration of cold-pressed oils and the brands patented TFC8 technology.

Augustinus Bader is a London-based science-driven premium skincare brand. It was launched in 2018 to help fund research into burn repair, skin graft prevention and scar minimisation.

The brand was founded by Professor Augustinus Bader who is a pioneer in the field of stem cell biology. Backed by more than 30-years of research and innovation, Bader developed a ground-breaking wound-gel in 2008 that helped regenerate skin affected by third-degree burns without surgery.

The Face Oil leverages Professor Augustinus Baders extensive stem cell biology expertise. It instantly hydrates the skin and retains moisture without leaving any greasy residue. It also minimises fine lines and wrinkles, reduces hyper-pigmentation and boosts cellular renewal.

The Face Oil offers a powerful blend of Babassu Oil, Argan Oil, Hazelnut Oil, Karanja Oil and TFC8

The Face Oil is made with a potent blend of Babassu Oil, Argan Oil, Hazelnut Oil, Karanja Oil and TFC8. Babassu Oil is a vitamin-rich seed oil which protects the skin against environmental aggressors, while Argan oil helps restore the skins hydrolipidic film and prevents trans-epidermal water loss.

Hazelnut Oil supports the skins moisture retention, while Karanja Oil delivers soothing antimicrobial properties and prevents premature ageing. Finally, TFC8 an exclusive patented complex of amino acids and vitamins boots internal skin repair and renewal.

We wanted to offer our customers the option between a rich cream, a light cream, and now, an oil, so they can select the texture that works best for their facial skincare routine, commented Professor Bader. Each of these offerings contains our specialised compound TFC8, which transport natural mechanisms for skin repair. As long as you have one product with TFC8, you will see results.

Augustinus Bader officially launched The Cream and The Rich Cream in 2018. The brand made its travel retail debut at TFWA World Exhibition in Cannes in 2019 and plans to further extend its footprint in the channel at the upcoming Moodie Davitt Virtual Travel Retail Expo this October, where it is exhibiting at #Virtual Stand BT-S9.

Professor Augustinus Bader leverages more than 30 years of stem cell biology expertise to formulate his luxury skincare range

Augustinus Bader is a Silver Partner at the inaugural Moodie Davitt Virtual Travel Retail Expo.

The unique 5-day live event, followed by a 30-day showcase, begins on 12 October, just after the conclusion of the Chinese Golden Week holidays. It features a star-studded series of events across the five days, including a Symposium, category workshops and a new consumer research initiative.

Registration is free for buyers, exhibitors and preferred media partners. (Clickhereto register)

Read the rest here:
Enhancing overall facial skin wellness: Augustinus Bader reveals The Face Oil - The Moodie Davitt Report - The Moodie Davitt Report

Researchers identify a compound that inhibits growth of schwannomas – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Sep 21 2020

Schwannomas are tumors of the peripheral nervous system, which often occur in the genetic disease neurofibromatosis type 2.

The research group of Prof. Dr. Helen Morrison at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, identified a compound that inhibits the growth of such tumors and improves nerve function.

In a new project, the group will now conduct a multi-center preclinical study together with three German partners. The BMBF is funding this step towards a therapeutic application with a grant of 1.45 million euro over 3 years.

Jena. A schwannoma is a benign tumor of the peripheral nervous system. It usually results from an abnormal overgrowth of Schwann cells, a cell type covering nerve fibers and supporting them in their function.

Following nerve damage, Schwann cells divide to support regeneration in sufficient numbers. However, if cell division is not limited in time, over-proliferation of Schwann cells occurs and causes schwannoma formation.

These progressively growing tumors compress nerve cells, impairing nerve function and causing symptoms such as paralysis or pain.

Schwannomas often appear in the context of the hereditary disease neurofibromatosis type 2 (NF2), which causes uncontrolled growth of nervous and connective tissues, particularly surrounding the 8th cranial nerve. Consequently, loss of hearing and balance are frequent symptoms of NF2.

Prof. Dr. Helen Morrison and her research group "Nerve Regeneration" at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, is studying the role of Schwann cells in the peripheral nervous system.

The team was able to identify a molecule that inhibits schwannoma growth. The protein Neuregulin 1 (Nrg1) occurs naturally in the body and induces differentiation of Schwann cells, including termination of cell division following nerve regeneration.

However, in the case of the hereditary disease NF2 and likely other schwannomas, Nrg1 is strongly downregulated. Without this stop signal, Schwann cells fail to differentiate, continue to divide and form schwannomas.

Therapy options are very limited and focus on surgical removal, often causing additional nerve damage and entailing a high recurrence rate. Novel approaches are urgently needed to improve tumor therapy and patient's quality of life.

Prof. Dr. Morrison's group has already shown that Nrg1 inhibits schwannoma growth and improves nerve function in a mouse model.

Her current project aims to develop this approach further towards clinical application. Previous studies on heart diseases have classified Nrg1 as safe for use in humans.

Now, the research group has successfully obtained funding to conduct a multi-centric, preclinical study. Starting from August 2020, the German Federal Ministry of Education and Research (BMBF) will fund this study for 3 years with a total sum of 1.45 million euro, of which approximately 732,000 euro will go to FLI.

We are very pleased about this support and see this as encouragement of our research," says Prof. Morrison, who has many years of experience in research on the hereditary disease NF2. "Together with our partners we hope to contribute to the development of a drug to help people affected by this disease."

Headed by Prof. Dr. Morrison of the FLI, the research team also includes the partner laboratories of Dr. Robert Fledrich and Dr. Ruth Stassart of the University Hospital Leipzig and Prof. Dr. Reinhard Bauer at the Institute of Molecular Cell Biology of Jena University Hospital.

The teams' research approach is unprecedented: Following standards of clinical patient trials, three centers will conduct parallel, randomized and blinded experiments following a preregistered study protocol.

Study design as well as statistical data analysis is conducted independently by the team of Prof. Dr. Andr Scherag of the Institute for Medical Statistics, Computer and Data Sciences of Jena University Hospital. Collectively, these measures strongly increase the studies' validity and significance.

The research network will be further supported by a funded membership of the TMF (Technologie- und Methodenplattform fr die vernetzte medizinische Forschung e.V.), that will enable a broad exchange with experts on diverse methods crucial to networked medical research (e.g. research data management).

Additionally, all projects of the current BMBF funding line will be counseled by the partner project "DECIDE" located at the Charit in Berlin.

We are looking forward to the interaction with all these different experts to apply highest standards to our preclinical study."

Dr. Helen Morrison, Professor, Leibniz Institute on Aging - Fritz Lipmann Institute

The new BMBF funding line for preclinical studies supports innovative research projects aiming to expedite translation of important research findings from basic research to clinical application. This aim is shared by the [emailprotected] program, which supported the preceding work leading up to the current preclinical study.

Dr. Sonja Schtzlein, head of [emailprotected], sees the current funding as a success: "I am pleased to see that SPARK has contributed to advancing the project to this important step towards an application-oriented therapy by providing financial support, advice and arranging mentoring partners from industry."

Continued here:
Researchers identify a compound that inhibits growth of schwannomas - News-Medical.Net

University of Edinburgh spinout Cellinta will develop gene therapies for cancer – PharmaTimes

A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer.

The company, Cellinta Limited, was born out of research from scientists at the University of Edinburgh, and received funding through investments from SV Health Investors and Cancer Research UK.

The funding will be used to develop a pipeline of highly selective gene therapies targeting cancer stem cells in a variety of solid tumour types.

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics.

Cellinta has entered into a collaborative research agreement with the University, and retains the option to license intellectual property developed from research conducted there.

Professor Pollard will join the Cellinta team as scientific founder and a senior adviser, while Dr Soraya Bekkali will take the helm as chief executive officer of the new company.

I am delighted to be leading such an exciting company, said Dr Bekkali.

Cellintas approach offers the opportunity to deliver combinations of therapies selectively to cancer stem cells, bypassing the limitations of traditional treatments which often target single genes or redundant signalling pathways, she added.

Meanwhile, Mike Ross managing partner at London-based SV Health Investors has been appointed chairman of Cellinta.

Cellinta represents a unique opportunity to build a leading company based on exciting and innovative science, with the potential to develop first-in-class therapies, said Ross.

We are delighted with the progress the company has made and extremely pleased to appoint Soraya, who has deep experience in gene therapy across various therapeutic areas, as CEO. We look forward supporting Cellinta in its progress as a pioneer in the field, he added.

See the original post here:
University of Edinburgh spinout Cellinta will develop gene therapies for cancer - PharmaTimes

A Drug Used to Treat Deadly Coronavirus Infections in Cats May Be an Effective Treatment Against COVID-19 – SciTechDaily

In a search for COVID-19 treatments, researchers pursue a drug used on cats.

University of Alberta researchers worked with SLAC X-ray scientists to explore the potential of a feline coronavirus drug that may be effective against SARS-CoV-2.

Researchers at the University of Alberta have shown that a drug used to treat deadly coronavirus infections in cats could potentially be an effective treatment against SARS-CoV-2, the virus behind the global coronavirus pandemic. Theresults were published in the journal Nature Communications.

The study, which was aided by scientists at the U.S. Department of Energys SLAC National Accelerator Laboratory, paves the way for human clinical trials, which should begin soon, said Joanne Lemieux, a professor of biochemistry at the University of Alberta and the studys senior author.

Joanne Lemieux and a team at the University of Alberta found that a drug used in cats may help treat SARS-CoV-2 infections. Credit: Image courtesy Joanne Lemieux

This drug is very likely to work in humans, so were encouraged that it will be an effective treatment for COVID-19 patients, Lemieux said, although the clinical trials will need to run their course before anyone can be sure that the drug, a protease inhibitor called GC376, is both safe and effective for treating COVID-19 in humans.

In cats at least, GC376 works by interfering with a virus ability to replicate, thus ending an infection. Derivatives of this drug were first studied following the 2003 outbreak of severe acute respiratory syndrome (SARS), and it was further developed by veterinary researchers who showed it cures fatal feline affliction.

Lemieux and colleagues at the University of Alberta first tested two variants of the feline drug against SARS-CoV-2 protein in test tubes and with the live virus in human cell lines, then crystallized the drug variants in conjunction with virus proteins. Working with Silvia Russi, a crystallographer and beamline scientist for the Structural Molecular Biology program at SLACs Stanford Synchrotron Radiation Lightsource (SSRL), the researchers determined the orientation of the cat drug as it bound to an active site on a SARS-CoV-2 protein, revealing how it inhibits viral replication.

This will allow us to develop even more effective drugs, Lemieux said, and the team will continue to test modifications of the inhibitor to make it an even better fit inside the virus.

Aina Cohen, a SLAC senior scientist and co-division head of Structural Molecular Biology at SSRL, said she was excited by the drugs effectiveness and by SSRLs ability to help out. Until an effective vaccine can be developed and deployed, drugs like these add to our arsenal of COVID-19 treatments, she said. We are thrilled to learn of these important results and look forward to learning the outcome of clinical trials.

Reference: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication by Wayne Vuong, Muhammad Bashir Khan, Conrad Fischer, Elena Arutyunova, Tess Lamer, Justin Shields, Holly A. Saffran, Ryan T. McKay, Marco J. van Belkum, Michael A. Joyce, Howard S. Young, D. Lorne Tyrrell, John C. Vederas and M. Joanne Lemieux, 27 August 2020,Nature Communications.DOI: 10.1038/s41467-020-18096-2

The research was funded by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada. Extraordinary SSRL operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. SSRL is a DOE Office of Science user facility. The Structural Molecular Biology Program at SSRL is supported by the DOE Office of Science and by the National Institutes of Health, National Institute of General Medical Sciences.

Read more:
A Drug Used to Treat Deadly Coronavirus Infections in Cats May Be an Effective Treatment Against COVID-19 - SciTechDaily

Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as…

SAN FRANCISCO and SUZHOU, China, Sept. 20, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, jointly announce with Eli Lilly and Company ("Lilly", NYSE: LLY) that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements. The National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for this indication. Biomarker data analysis revealed that the MHC-II antigen presentation pathway played a key role in immunotherapy-chemotherapy combination. Higher gene expression of this pathway was significantly associated with longer progression-free survival (HR, 0.41; 95% CI, 0.23-0.76; P=0.0041) and could potentially serve as a predictive biomarker to select patients who can benefit from this regimen.

Professor Li ZHANG, Head of Department of Internal Medicine, Sun Yat-sen University Cancer Center, the primary investigator of the ORIENT-11 trial, stated: "Sintilimab in combination with pemetrexed and platinum chemotherapy showed improved efficacy and no new safety signals in locally advanced or metastatic nonsquamous NSCLC. These results will further our understanding of the performance of this combination in certain types of patients."

Dr. Wei XU, Vice President of New Drug Biology and Translational Medicine of Innovent, stated: "We were very pleased to release these biomarker results at the ESMO Virtual Congress 2020. MHC-II antigen presentation pathway might predict clinical efficacy of immunotherapy-chemotherapy. This finding could improve our understanding of the mechanism of action of this combination and provide a scientific rationale for future selection of patients who could benefit most."

Dr. Li WANG, Senior VP of Lilly China and Head of Lilly China Drug Development and Medical Affairs Center, stated: "Biomarker exploration is very important to advance cancer immunotherapy. We are very pleased that our discovery of a potential biomarker for immunotherapy will be shared at ESMO. I would like to thank all the investigators, scientists and patients involved in the trial."

About ORIENT-11 Trial

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating the efficacy and safety of TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements (ClinicalTrials.gov, NCT03607539). The primary endpoint is progression-free survival (PFS) assessed by Independent Radiographic Review Committee based on RECIST v1.1. The key secondary endpoints include overall survival (OS) and safety profile.

A total of 397 subjects have been enrolled in the ORIENT-11 trial and randomized in a 2:1 ratio to receive either TYVYT (sintilimab injection) 200mg or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy every three weeks for up to four cycles, followed by either TYVYT (sintilimab injection) or placebo plus ALIMTA (pemetrexed) maintenance therapy. The subjects will receive treatment until radiographic disease progression, unacceptable toxicity or any other conditions that require treatment discontinuation. Conditional crossover is permitted.

About nsqNSCLC

Lung cancer is a malignancy with the highest morbidity and mortality in China. NSCLC accounts for about 80 to 85 percent of lung cancer. Approximately 70 percent of NSCLC is locally advanced or metastatic at initial diagnosis, resulting in patients with having little to no chance of radical resection. Meanwhile, even after radical surgery, patients have a high chance of recurrence and eventually die from disease progression. About 70 percent of NSCLC in China is nonsquamous subtype and 50 percent of nsqNSCLC is without sensitizing EGFR mutations or ALK rearrangements. These patients do not respond well to targeted therapy and there are limited treatment options available to them.

About TYVYT (Sintilimab Injection)

TYVYT (sintilimab injection), an innovative drug with global quality standards jointly developed in China by Innovent and Lilly, has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy, and included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List (NRDL) in November 2019. In April 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with ALIMTA (pemetrexed) and platinum chemotherapy as first-line therapy in nonsquamous non-small cell lung cancer (NSCLC). In May 2020, TYVYT (sintilimab injection) monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma. In August 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with GEMZAR (gemcitabine for injection) and platinum chemotherapy as first-line therapy in squamous NSCLC.

TYVYT (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies for TYVYT (sintilimab injection) to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Meanwhile, Innovent is conducting clinical research studies on TYVYT (sintilimab injection) worldwide.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with three products, TYVYT (sintilimab injection), BYVASDA (bevacizumab injection) and SULINNO (adalimumab injection), on market, one asset under NDA review with priority review status, four assets in Phase 3 or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: http://www.innoventbio.com.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and lilly.com/newsroom.

About Innovent Biologics' strategic collaboration with Eli Lilly and Company

Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 a groundbreaking partnership between a Chinese pharmaceutical company and a multinational pharmaceutical company. Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China. In October 2015, the two companies announced the extension of their existing collaboration to include co-development of three additional oncology antibodies targeting oncology indications. In August 2019, Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. Its collaboration with Lilly indicates that Innovent has established a comprehensive level of cooperation between China's innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D, CMC, clinical development and commercialization. In August, 2020, Lilly and Innovent announced a global expansion of their strategic alliance for TYVYT (sintilimab injection), and Lilly will obtain an exclusive

license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets.

TYVYT (sintilimab injection, Innovent)

ALIMTA and GEMZAR are trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Disclaimer:

1. This indication is still under clinical trial, which hasn't been approved in China. 2. Innovent does not recommend any off-label usage.3. For medical and healthcare professional use only.

View original content:http://www.prnewswire.com/news-releases/innovent-and-lilly-release-biomarker-results-of-tyvyt-sintilimab-injection-in-combination-with-alimta-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-nonsquamous-non-small-cell-lung-cancer-at-esmo-virtual-co-301134412.html

SOURCE Innovent Biologics, Inc.

Company Codes: HongKong:1801, OTC-PINK:IVBIY

The rest is here:
Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as...